Speaker illustration

Professor Michel Krempf

Nantes (France)

Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

Event: ESC Congress 2018

Topic: Lipid-Lowering Agents

Session: Innovative drug therapies


What is atherogenic dyslipidaemia? Does it really exist?

Event: ESC CONGRESS 2014

Topic: Epidemiology, lipids

Session: Combination therapy in dyslipidaemia. What is new in Europe?


ESC 365 is supported by